ReviewJournal of Parkinson's disease2013
Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments.
Review in Journal of Parkinson's disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.Journal of Parkinson's disease · 2017Trial
- Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.Journal of Parkinson's disease · 2024Review
- Article
- Waiting for PARIS-A Biological Target in Search of a Drug.Journal of Parkinson's disease · 2022Article
- Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Article
- Seeking progress in disease modification in Parkinson disease.Parkinsonism & related disorders · 2021Review
- Drug Repurposing for Parkinson's Disease: The International Linked Clinical Trials experience.Frontiers in neuroscience · 2021Review
- Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.Expert opinion on investigational drugs · 2020Review
- Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer.Journal of Parkinson's disease · 2020Review
- Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.Innovations in clinical neuroscience · 2020Review
- Neuroprotection by the Immunomodulatory Drug Pomalidomide in theFrontiers in aging neuroscience · 2020Article
- Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2019Article
- Article
- Effect of NAC treatment and physical activity on neuroinflammation in subchronic Parkinsonism; is physical activity essential?Journal of neuroinflammation · 2018Article
- Drug Repurposing in Parkinson's Disease.CNS drugs · 2018Review
- An early diagnosis is not the same as a timely diagnosis of Parkinson's disease.F1000Research · 2018Review
- Unexpected Exacerbation of Neuroinflammatory Response After a Combined Therapy in Old Parkinsonian Mice.Frontiers in cellular neuroscience · 2018Article
- c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism.Frontiers in pharmacology · 2018Article
- Nilotinib - Differentiating the Hope from the Hype.Journal of Parkinson's disease · 2016Article
- Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Funding
Abstract
Finding new therapies for Parkinson's disease (PD) is a slow process. We assembled an international committee of experts to examine drugs potentially suitable for repurposing to modify PD progression. This committee evaluated multiple drugs currently used, or being developed, in other therapeutic areas, as well as considering several natural, non-pharmaceutical compounds. The committee prioritized which of these putative treatments were most suited to move immediately into pilot clinical trials. Aspects considered included known modes of action, safety, blood-brain-barrier penetration, preclinical data in animal models of PD and the possibility to monitor target engagement in the brain. Of the 26 potential interventions, 10 were considered worth moving forward into small, parallel 'learning' clinical trials in PD patients. These trials could be funded in a multitude of ways through support from industry, research grants and directed philanthropic donations. The committee-based approach to select the candidate compounds might help rapidly identify new potential PD treatment strategies for use in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.